In a pioneering study published in Cancer Immunology Research, researchers have identified a novel strategy to improve the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in treating solid tumors. The research, led by Dr. Russell W. Jenkins from the Mass General Cancer Center, explores the role of TBK1 inhibition in enhancing CAR T-cell efficacy. This innovative approach uses patient-derived organotypic tumor spheroids (PDOTS) to model the tumor microenvironment and investigate treatment resistance mechanisms.

Understanding Treatment Resistance in Solid Tumor Therapies

The study delves into why CAR T-cell therapy, while effective for blood cancers, faces challenges when applied to solid tumors. Researchers utilized a sophisticated 3D microfluidic model that mimics the tumor's natural environment more accurately than traditional models. They discovered that after initial exposure to target cells, CAR T-cells exhibit increased expression of inhibitory receptors, leading to dysfunction and reduced efficacy.

This discovery was made possible through the use of PDOTS, which replicate key features of the tumor microenvironment. These models allowed researchers to observe interactions between tumors and immune cells in unprecedented detail. By inhibiting the function of TBK1, a gene linked to immune evasion, they were able to restore CAR T-cell activity, prevent dysfunction, and boost T-cell proliferation. Moreover, TBK1 inhibition made cancer cells more susceptible to immune cell targeting and destruction, offering a promising avenue for overcoming treatment resistance.

Collaborative Efforts and Future Implications

The success of this study is attributed to extensive collaboration among multiple institutions and experts. Initially sparked by conversations over coffee with Dr. Soldano Ferrone, the project evolved into a comprehensive investigation involving his daughter, Cristina Ferrone, and other collaborators at Massachusetts General Hospital. The team leveraged PDOTS models to test CAR T-cells provided by the Ferrone lab, uncovering significant insights into treatment resistance.

The clinical implications of these findings are profound. Targeting TBK1 could reduce resistance and enhance CAR T-cell efficacy in solid tumors expressing B7-H3, a common antigen. Additionally, the study demonstrates the feasibility and utility of using PDOTS to study tumor-immune cell interactions. Resources such as robust tissue banking infrastructure and single-cell RNA sequencing played crucial roles in supporting this research. Funding from the Massachusetts Life Sciences Center enabled the acquisition of essential instrumentation, further advancing the project's objectives.